917889-25-9

Upstream product

• 5372-81-6 dimethyl aminoterephthalate 
• 1195-45-5 para-fluorophenyl isocyanate 

Downstream Products

• 1373278-15-9 tert-butyl 5-(3-(4-fluorophenyl)-4-oxo-7-(5-phenylisoxazol-3-yl)-3,4-dihydroquinazolin-2-yl)pentanoate 
• 1373274-67-9 5-(3-(4-fluorophenyl)-4-oxo-7-(5-phenylisoxazol-3-yl)-3,4-dihydroquinazolin-2-yl)pentanoic acid 
• 1373278-18-2 tert-butyl 5-(7-carbamoyl-3-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)pentanoate 
• 1373278-19-3 tert-butyl 5-(3-(4-fluorophenyl)-4-oxo-7-(1H-1,2,4-triazol-5-yl)-3,4-dihydroquinazolin-2-yl)pentanoate 
• 1373274-75-9 5-(3-(4-fluorophenyl)-4-oxo-7-(1H-1,2,4-triazol-5-yl)-3,4-dihydroquinazolin-2-yl)pentanoic acid 
• 1373278-20-6 tert-butyl 5-(7-carbamothioyl-3-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)pentanoate 
• 1373278-21-7 tert-butyl 5-(3-(4-fluorophenyl)-4-oxo-7-(thiazol-2-yl)-3,4-dihydroquinazolin-2-yl)pentanoate 
• 1373274-76-0 5-(3-(4-fluorophenyl)-4-oxo-7-(thiazol-2-yl)-3,4-dihydroquinazolin-2-yl)pentanoic acid 
• 1373278-24-0 tert-butyl 5-(7-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)pentanoate 
• 1373274-78-2 5-(7-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)pentanoic acid 
• 1373278-74-0 tert-butyl 5-(3-(4-fluorophenyl)-4-oxo-7-(3-(4-(trifluoromethyl)benzyl)-1,2,4-oxadiazol-5-yl)-3.4-dihydroquinazolin-2-yl)pentanoate 
• 1373275-23-0 5-(3-(4-fluorophenyl)-4-oxo-7-(3-(4-trifluoromethylbenzyl)-1,2,4-oxadiazol-5-yl)-3,4-dihydroquinazolin-2-yl)pentanoic acid 
• 1373278-77-3 C₃₄H₃₂F₂N₄O₅ 
• 1373275-27-4 C₃₀H₂₄F₂N₄O₅ 

Relevant academic research and scientific papers

QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.

PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST

The present invention relates to a pharmaceutical composition containing one or more quinazoline compounds as an active ingredient, which has antagonistic activity against serotonin 5-HT3A and is effective for the prevention and treatment of ce

2,4-QUINAZOLINE DERIVATIVES HAVING ACTIVITY TO T-TYPE CALCIUM CHANNEL AND PREPARATION METHOD THEREOF

Disclosed are 2,4-dioxo-quinazoline derivative compounds of Formula 1 which is a selective antagonist with respect to a T-type calcium channel and can be developed as a drug for neurogenic pains, epilepsy or hypertension, and a preparation method thereof.